Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling

• Published in: Gut microbes 2024-12, Vol.16 (1), p.2390164
• Main Authors: Feng, Ruijia, Yang, Wenchao, Feng, Weiqi, Huang, Xiuyi, Cen, Meifeng, Peng, Guiyan, Wu, Wenrui, Wang, Zhecun, Jing, Yexiang, Long, Ting, Liu, Yunchong, Li, Zilun, Chang, Guangqi, Huang, Kan
• Format: Article
• Language: English
• Subjects: Aldehyde Oxidase - metabolism; Animals; Diet, High-Fat - adverse effects; Disease Models, Animal; Gastrointestinal Microbiome; gut microbiota; Hepatocytes - metabolism; Humans; Lipid Metabolism; Lipogenesis; Liver - metabolism; Male; Mice; Mice, Inbred C57BL; Niacinamide - metabolism; nicotinamide metabolism; Non-alcoholic fatty liver disease; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - microbiology; Research Paper; time-restricted feeding
• ISSN: 1949-0976; 1949-0984; 1949-0984
• DOI: 10.1080/19490976.2024.2390164

Non-alcoholic fatty liver disease (NAFLD) has emerged as a global health concern, lacking specific therapeutic strategies. Time-restricted feeding (TRF) regimen demonstrated beneficial effects in NAFLD; however, the underlying mechanisms remain unclear. In this study, we established a NAFLD mouse model through a high-fat diet (HFD) and implemented the 16:8 TRF regimen for a duration of 6 weeks. We demonstrated that TRF remarkably alleviated hepatic steatosis in HFD mice. Of note, aldehyde oxidase 1 (AOX1), a key enzyme in hepatic nicotinamide (NAM) catabolism, exhibited apparent upregulation in response to HFD, leading to abnormal accumulation of N-Methyl-6-pyridone-3-carboxamide (N-Me-6-PY, also known as 2PY) and N-Methyl-4-pyridone-5-carboxamide (N-Me-4-PY, also known as 4PY), whereas it was almost restored by TRF. Both N-Me-6-PY and N-Me-4-PY promoted de novo lipogenesis and fatty acid uptake capacities in hepatocyte, and aggravated hepatic steatosis in mice either fed chow diet or HFD. In contrast, pharmacological inhibition of AOX1 was sufficient to ameliorate the hepatic steatosis and lipid metabolic dysregulation induced by HFD. Moreover, transplantation of fecal microbiota efficiently mimicked the modulatory effect of TRF on NAM metabolism, thus mitigating hepatic steatosis and lipid metabolic disturbance, suggesting a gut microbiota-dependent manner. In conclusion, our study reveals the intricate relationship between host NAM metabolic modification and gut microbiota remodeling during the amelioration of NAFLD by TRF, providing promising insights into the prevention and treatment of NAFLD.